Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEVPRO-3 phase 3 trial of mevrometostat plus enzalutamide in metastatic castration-sensitive prostate cancer
MOH_2025-09-03_014315Phase 3Recruiting
- Sponsor
- Pfizer
- Start
- Jul 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of mevrometostat and enzalutamide in prostate cancer (PCa) (2 arms), sponsored by Pfizer. Primary endpoint: Radiographic progression-free survival. Started Jul 2025; status: recruiting.
02
Drugs
mevrometostatenzalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on MOH_2025-09-03_014315.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-09-03_014315.